Form 6K Biontech Se For: 24 March
- Investing.com
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
BioNTech SE (BNTX)
This is the main Biontech stock price chart and current quotes. You can find more details about BNTX stock by going to one of our multiple sections under this page such as historical data, price charts, technical analysis and others.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
85.05
87.96
52 wk Range
79.52
124.00
BNTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
85.0587.96
52 wk Range
79.52124.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BNTX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
131.22
Upside
+53.15%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings downwards for the upcoming period
- Biontech Se receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Form 6K Biontech Se For: 24 March
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
BioNTech SE SWOT Analysis
Beyond COVID-19 | Explore BioNTech's strategic shift from its COVID-19 vaccine success to a diversified portfolio, including promising candidates like BNT327 and BNT324 in oncology. |
Analyst Optimism | Price targets range from $125 to $134, reflecting confidence in BioNTech's long-term potential despite current challenges. The average price target stands at $128.75. |
Financial Fortitude | With $18 billion in cash and a strong gross profit margin, BioNTech maintains financial flexibility for R&D investments despite projected near-term revenue declines. |
Oncology Powerhouse | BioNTech leverages mRNA expertise to build a robust oncology pipeline, aiming for 10 new approvals by 2030 and positioning itself as a leader in cancer treatment innovation. |
BioNTech SE Earnings Call Summary for Q4/2024
- BioNTech's Q4 EPS of $1.08 and revenue of $1.19B beat forecasts, yet stock fell 2.88% pre-market
- 2024 net loss of €665M, down from €930M profit in 2023; total revenue fell to €2.8B from €3.8B
- 2025 revenue projected at €1.7-2.2B; R&D expenses expected to be €2.6-2.8B
- Focus on oncology expansion, with multiple clinical data updates and potential regulatory submissions planned
- Strong cash position of €17.4B, but high R&D costs and negative EPS forecasts raise profitability concerns
Last Updated: 03/10/2025, 09:36 AM
Read Full TranscriptCompare BNTX to Peers and Sector
Metrics to compare | BNTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBNTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −15.7x | 9.9x | −0.4x | |
PEG Ratio | 0.23 | −0.32 | 0.00 | |
Price / Book | 0.9x | 2.3x | 2.6x | |
Price / LTM Sales | 6.2x | 4.3x | 3.1x | |
Upside (Analyst Target) | 51.2% | 23.3% | 56.0% | |
Fair Value Upside | Unlock | 12.5% | 9.0% | Unlock |
Analyst Ratings
14 Buy
5 Hold
0 Sell
Ratings:
19 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 131.22
(+53.15% Upside)
Earnings
Latest Release
Mar 10, 2026
EPS / Forecast
-1.25 / -0.25
Revenue / Forecast
907.4M / 763.47M
People Also Watch
FAQ
What Is the BioNTech (BNTX) Stock Price Today?
The BioNTech stock price today is 85.68 USD.
What Stock Exchange Does BioNTech Trade On?
BioNTech is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for BioNTech?
The stock symbol for BioNTech is "BNTX."
What Is the BioNTech Market Cap?
As of today, BioNTech market cap is 20.56B USD.
What Is BioNTech's Earnings Per Share (TTM)?
The BioNTech EPS (TTM) is -4.70.
When Is the Next BioNTech Earnings Date?
BioNTech will release its next earnings report on May 11, 2026.
From a Technical Analysis Perspective, Is BNTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has BioNTech Stock Split?
BioNTech has split 0 times.
How Many Employees Does BioNTech Have?
BioNTech has 7807 employees.
What is the current trading status of BioNTech (BNTX)?
As of Mar 29, 2026, BioNTech (BNTX) is trading at a price of 85.68 USD, with a previous close of 87.46 USD. The stock has fluctuated within a day range of 85.05 USD to 87.96 USD, while its 52-week range spans from 79.52 USD to 124.00 USD.
What Is BioNTech (BNTX) Price Target According to Analysts?
The average 12-month price target for BioNTech is 131.22 USD, with a high estimate of 170.62607895 USD and a low estimate of 75.58061917 USD. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +53.15% Upside potential.
What Is the BNTX Premarket Price?
BNTX's last pre-market stock price is 87.11 USD. The pre-market share volume is 3,170.00, and the stock has decreased by -0.35, or -0.40%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.